"Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).

TPS4600Background: Tivozanib is a biochemically potent and selective VEGF tyrosine kinase inhibitor in clinical development in RCC. Other agents used for treatment of RCC inhibit multiple tyrosine ... Click to show full abstract

Keywords: randomized controlled; multi center; rcc; tivo phase; phase randomized; controlled multi

Journal Title: Journal of Clinical Oncology
Year Published: 2017

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
0

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended